Lowest Price Guaranteed
Slides
121
Last Updated
July 2026
View Count
12985
EXCEL DELIVERABLE
Spreadsheet I includes details on the key innovator companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, inputs for a detailed company competitiveness analysis and a shortlist of industry stakeholders that were deemed to be likely targets of mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated within.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in cell and gene therapies (since 2011).
Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed the means to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company.
Spreadsheet IV is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset.
Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.
Spreadsheet VI is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with cell and gene therapies.
Spreadsheet VII includes publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on likely returns on investment received by the mentioned investors.
POWERPOINT DELIVERABLE
Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for cell and gene therapies. It goes on to discuss some of the key benefits of these medical products and their advantages over other available drugs / therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Section I: Need for Cell and Gene Therapies & Key Innovators Landscape
Chapter 5 describes the current need for cell and gene therapies, and highlights key facts about the origin and development of such ATMPs. It features information on current areas of innovation, along with the opinions of experts, describing the various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain, along with examples of ventures that have either succeeded or failed in the market. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts). It concludes with information on the different conferences that have been conducted in this domain in the recent past, and those that are planned for the near future.
Chapter 6 focuses on some of the key innovators (companies established on or after 2005) and features detailed analysis of the aforementioned companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and type of product. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies.
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely, treatment-related value offered, value to patients and technology related value, we developed an empirical framework to quantify the value proposition of a business.
Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developed of diverse cell and gene therapies captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criteria, which was informed via our company health indexing and valuation exercise.
Section II Analysis of Investments & Company Valuation
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report.
Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.
Section III Financial Analysis & Assessment of Business Risks
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall cell and gene therapy market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset.
Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.
Section IV Market Forecast & Opportunity Analysis
Chapter 14 features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall cell and gene therapy market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) ) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world) .
Section V Analysis of Returns on Investment & Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time.
Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 17 provides a pictorial summary of the overall project.
Chapter 18 is a set of appendices.
Excel Deliverable
1. Key Innovators & Products Dataset
1.1. Analysis Notes
1.2. Summary Dashboard
1.3. Innovators Landscape Dataset
1.4. Product Landscape Dataset
1.5. Company Health Indexing
1.6. Value Proposition Analysis
1.7. Key Acquisition Targets
A1 – A8 Appendices
2. Funding & Investments Analysis
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in cell and gene therapy
A1 – A2 Appendices
3. Company Valuation Analysis
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
A1 – A2 Appendices
4. Fundamental & Technical Financial Analysis
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
5. Business Risk Analysis
5.1. Analysis Notes
5.2. Business Risk Data
A1 – A2 Appendices
6. Market Forecast & Opportunity Analysis
6.1. Analysis Notes
6.2. Summary Dashboard
6.3. Market Forecast & Opportunity Analysis
A1 – A2 Appendices
7. Returns on Investment
7.1. Analysis Notes
7.2. Estimated RoI for Investors in Company A
7.3. Estimated RoI for Investors in Company B
7.4. Estimated RoI for Investors in Company C
7.5. Estimated RoI for Investors in Company D
7.6. Estimated RoI for Investors in Company E
7.7. Estimated RoI for Investors in Company F
7.8. Estimated RoI for Investors in Company G
7.9. Estimated RoI for Investors in Company H
7.10. Estimated RoI for Investors in Company I
7.11. Estimated RoI for Investors in Company J
A1 – A2 Appendices
PowerPoint Deliverable
1. Context
2. Project Approach
3. Project Objectives
4. Executive Summary
Section I: Need for Cell and Gene Therapy & Key Innovators Landscape
5. The Cell and Gene Therapy Market
5.1. Overview
5.2. Contemporary Sentiments & Expert Opinions
5.3. Key Areas of Application
5.4. Benefits of Cell and Gene Therapies
5.5 Developmental History
5.6 Exemplary Products
5.7. Challenges related to Cell and Gene Therapies
5.7 Key Initiatives in the Cell and Gene Therapy Market (Case Studies)
5.8.1. Exemplary Business Successes
5.8.2. Exemplary Business Failures
5.9. Analysis of Recent Conferences
6. Key Innovators Competitive Landscape
6.1. Key Innovators in the Cell and Gene Therapy Market
6.2. Analysis of Developer Landscape
7. Products Landscape & Company Health Indexing
7.1. List of Products
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
7.3. Concluding Remarks
8. Value Proposition Analysis
8.1. Overview & Methodology
8.2. Therapy Related Value
8.3. Value to Patients
8.4. Technology Related Value
8.5. Developer Value
9. Company Competitiveness Analysis
9.1. Overview & Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks
Section II Analysis of Investments & Company Valuation
10. Funding and Investments Analysis
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography
10.4. Most Active Companies and Popular Investors
10.5. Analysis of Trends Associated with Individual Funding Categories
10.6. Funding and Investments Summary
11. Company Valuation Analysis
11.1. Overview & Methodology
11.2. Results of Valuation Analysis
Section III Financial Analysis & Assessment of Business Risks
12. Financial Analysis of Public Ventures
12.1. Overview
12.2. Company A
12.2.1. Fundamental Analysis of Company Financials
12.2.1.1. Insights from Balance Sheet
12.2.1.2. Analysis of Financial Ratios
12.2.2. Technical Analysis of Stock Price
12.2.2.1. Historical Trends
12.2.2.1. Recent Trends
12.3. Company B
12.3.1. Fundamental Analysis of Company Financials
12.3.1.1. Insights from Balance Sheet
12.3.1.2. Analysis of Financial Ratios
12.3.2. Technical Analysis of Stock Price
12.3.2.1. Historical Trends
12.3.2.1. Recent Trends
12.4. Company C
12.4.1. Fundamental Analysis of Company Financials
12.4.1.1. Insights from Balance Sheet
12.4.1.2 Analysis of Financial Ratios
12.4.2. Technical Analysis of Stock Price
12.4.2.1. Historical Trends
12.4.2.1. Recent Trends
12.5. Company D
12.5.1. Fundamental Analysis of Company Financials
12.5.1.1. Insights from Balance Sheet
12.5.1.2. Analysis of Financial Ratios
12.5.2. Technical Analysis of Stock Price
12.5.2.1. Historical Trends
12.5.2.1. Recent Trends
12.6. Company E
12.6.1. Fundamental Analysis of Company Financials
12.6.1.1. Insights from Balance Sheet
12.6.1.2 Analysis of Financial Ratios
12.6.2. Technical Analysis of Stock Price
12.6.2.1. Historical Trends
12.6.2.1. Recent Trends
12.7. Company F
12.7.1. Fundamental Analysis of Company Financials
12.7.1.1. Insights from Balance Sheet
12.7.1.2 Analysis of Financial Ratios
12.7.2. Technical Analysis of Stock Price
12.7.2.1. Historical Trends
12.7.2.1. Recent Trends
12.8. Company G
12.8.1. Fundamental Analysis of Company Financials
12.8.1.1. Insights from Balance Sheet
12.8.1.2 Analysis of Financial Ratios
12.8.2. Technical Analysis of Stock Price
12.8.2.1. Historical Trends
12.8.2.1. Recent Trends
12.9. Company H
12.9.1. Fundamental Analysis of Company Financials
12.9.1.1. Insights from Balance Sheet
12.9.1.2 Analysis of Financial Ratios
12.9.2. Technical Analysis of Stock Price
12.9.2.1. Historical Trends
12.9.2.1. Recent Trends
12.10. Company I
12.10.1. Fundamental Analysis of Company Financials
12.10.1.1. Insights from Balance Sheet
12.10.1.2 Analysis of Financial Ratios
12.10.2. Technical Analysis of Stock Price
12.10.2.1. Historical Trends
12.10.2.1. Recent Trends
12.11. Company J
12.11.1. Fundamental Analysis of Company Financials
12.11.1.1. Insights from Balance Sheet
12.11.1.2 Analysis of Financial Ratios
12.11.2. Technical Analysis of Stock Price
12.11.2.1. Historical Trends
12.11.2.1. Recent Trends
13. Business Risk Analysis
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.8. Business Risk Summary
Section IV Market Forecast & Opportunity Analysis
14. Market Forecast and Opportunity Analysis
14.1. Overview and Methodology
14.2. Overall Cell and Gene Therapy Market Size, 2021-2035
14.2.1. Analysis by Key Market Segments
14.2.2. Analysis by Geography
14.2.3. Concluding Remarks
Section V Analysis of Returns on Investment & Key Acquisition Targets
15. Analysis of Returns on Investment
15.1. Overview & Methodology
15.2. Case Studies
15.3. Concluding Remarks
16. Key Acquisition Targets
16.1. Overview
16.2. List of Key Acquisition Targets
16.3. Concluding Remarks
17. Conclusion
18. Appendices
Please reach out to our team for the details.